These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15731917)

  • 1. In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines.
    Tanaka R; Ariyama H; Qin B; Takii Y; Baba E; Mitsugi K; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):595-601. PubMed ID: 15731917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro sequence-dependent interaction between nedaplatin and paclitaxel in human cancer cell lines.
    Tanaka R; Takii Y; Shibata Y; Ariyama H; Qin B; Baba E; Kusaba H; Mitsugi K; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):279-85. PubMed ID: 15875187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines.
    Qin B; Tanaka R; Shibata Y; Arita S; Ariyama H; Kusaba H; Baba E; Harada M; Nakano S
    Anticancer Drugs; 2006 Apr; 17(4):445-53. PubMed ID: 16550003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells.
    Fujie Y; Yamamoto H; Ngan CY; Takagi A; Hayashi T; Suzuki R; Ezumi K; Takemasa I; Ikeda M; Sekimoto M; Matsuura N; Monden M
    Jpn J Clin Oncol; 2005 Aug; 35(8):453-63. PubMed ID: 16024531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro.
    Tanaka R; Ariyama H; Qin B; Shibata Y; Takii Y; Kusaba H; Baba E; Mitsugi K; Harada M; Nakano S
    Oncol Rep; 2005 Sep; 14(3):683-8. PubMed ID: 16077975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel and radiotherapy: sequence-dependent efficacy--a preclinical model.
    Niero A; Emiliani E; Monti G; Pironi F; Turci L; Valenti AM; Marangolo M
    Clin Cancer Res; 1999 Aug; 5(8):2213-22. PubMed ID: 10473108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell cycle-dependent antagonistic interactions between paclitaxel and gamma-radiation in combination therapy.
    Sui M; Dziadyk JM; Zhu X; Fan W
    Clin Cancer Res; 2004 Jul; 10(14):4848-57. PubMed ID: 15269161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
    Aissat N; Le Tourneau C; Ghoul A; Serova M; Bieche I; Lokiec F; Raymond E; Faivre S
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):305-13. PubMed ID: 17912526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines.
    Makiyama A; Qin B; Uchino K; Shibata Y; Arita S; Isobe T; Hirano G; Kusaba H; Baba E; Akashi K; Nakano S
    Anticancer Drugs; 2009 Feb; 20(2):123-30. PubMed ID: 19209029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs.
    Verheul HM; Qian DZ; Carducci MA; Pili R
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):329-39. PubMed ID: 17256134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential sensitivity of paclitaxel-induced apoptosis in human esophageal squamous cell carcinoma cell lines.
    Faried A; Faried LS; Kimura H; Sohda M; Nakajima M; Miyazaki T; Kato H; Kanuma T; Kuwano H
    Cancer Chemother Pharmacol; 2006 Feb; 57(3):301-8. PubMed ID: 16028102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Tsunoda S; Izumi T; Mori K; Fujii H; Yazawa Y; Mano H; Furukawa Y
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):505-13. PubMed ID: 15340759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines.
    Kano Y; Akutsu M; Tsunoda S; Furuta M; Yazawa Y; Ando J
    Oncol Res; 1998; 10(7):347-54. PubMed ID: 10063968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell cycle arrest and apoptosis induced by oxaliplatin (L-OHP) on four human cancer cell lines.
    William-Faltaos S; Rouillard D; Lechat P; Bastian G
    Anticancer Res; 2006; 26(3A):2093-9. PubMed ID: 16827150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptotic mechanism of paclitaxel-induced cell death in human head and neck tumor cell lines.
    Hsiao JR; Leu SF; Huang BM
    J Oral Pathol Med; 2009 Feb; 38(2):188-97. PubMed ID: 19200178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells in vitro.
    Lee JW; Park JK; Lee SH; Kim SY; Cho YB; Kuh HJ
    Anticancer Drugs; 2006 Apr; 17(4):377-84. PubMed ID: 16549994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel-induced apoptosis is blocked by camptothecin in human breast and pancreatic cancer cells.
    Jeansonne DP; Koh GY; Zhang F; Kirk-Ballard H; Wolff L; Liu D; Eilertsen K; Liu Z
    Oncol Rep; 2011 May; 25(5):1473-80. PubMed ID: 21331447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination effects of SC144 and cytotoxic anticancer agents.
    Oshima T; Cao X; Grande F; Yamada R; Garofalo A; Louie S; Neamati N
    Anticancer Drugs; 2009 Jun; 20(5):312-20. PubMed ID: 19322070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose oxaliplatin enhances the antitumor efficacy of paclitaxel in human gastric cancer cell lines.
    Gu J; Yamamoto H; Lu X; Ngan CY; Tsujino T; Konishi K; Takemasa I; Ikeda M; Nagata H; Hashimoto S; Matsuzaki T; Sekimoto M; Takagi A; Monden M
    Digestion; 2006; 74(1):19-27. PubMed ID: 16988507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.